Business context and reporting period
Entity and period: The supplied filing is ChromaDex Corporation’s audited Form 10-K for the fiscal year ended December 31, 2022, not a filing under the name Niagen Bioscience, Inc. It reports annual results; it does not provide standalone fourth-quarter financial statements.
ChromaDex develops and sells nicotinamide riboside (NR), branded as Niagen, including finished Tru Niagen supplements, and also sells other ingredients and analytical reference standards and services. Its three segments are Consumer Products, Ingredients, and Analytical Reference Standards and Services.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Net sales | $72.05 million | $67.45 million |
| Gross profit / margin | $42.80 million / 59.4% | $41.49 million / approximately 61.5% |
| Operating loss | $18.63 million | $27.07 million |
| Net loss | $16.54 million | $27.13 million |
| Loss per share, basic and diluted | $0.24 | $0.40 |
| Cash used in operating activities | $15.10 million | $24.16 million |
| Cash used in investing activities | $0.33 million | $0.41 million |
| Cash provided by financing activities | $7.65 million | $36.09 million |
At year-end, cash and cash equivalents were $20.44 million, including $0.2 million restricted; unrestricted cash was approximately $20.3 million. The company had no outstanding borrowings under its Western Alliance Bank credit line; borrowing availability was $6.1 million at year-end, subject to terms and conditions. Total liabilities were $25.39 million, including lease obligations and $3.96 million of deferred revenue. Inventory was $14.68 million, trade receivables $8.48 million, and accounts payable $9.68 million.
Management cited recurring losses, negative operating cash flow, inflation, and continuing COVID-19 effects as conditions considered in its liquidity assessment. It nevertheless expected unrestricted cash and cash generated from sales to cover obligations for at least 12 months from the financial-statement issuance date, while noting it may seek additional capital.
Changes versus the prior year
- Sales rose 7% ($4.60 million). Consumer Products sales increased 6% to $60.11 million; Ingredients sales increased 18% to $8.74 million; Analytical Reference Standards and Services sales declined 4% to $3.20 million.
- Gross profit increased 3%, but gross margin fell 210 basis points to 59.4%, primarily reflecting higher supply-chain staffing and wage costs and other inflationary pressures.
- Operating loss narrowed by $8.45 million. General and administrative expense fell 22%, mainly because legal expense declined $9.9 million; R&D expense rose 26% to $4.83 million.
- Net loss included $2.085 million of Employee Retention Tax Credit (ERTC) income. Excluding that credit, the reported net loss would have been higher; the filing does not present a separate adjusted net-loss measure.
- Operating cash use improved by approximately $9.1 million. Financing cash inflow fell sharply from 2021, when equity issuance and option exercises generated substantially more proceeds.
Outlook, material items and risks
- No quantified financial guidance: The filing provides no specific revenue, earnings, or margin forecast. Management describes priorities including growing Tru Niagen e-commerce and international distribution and developing the China opportunity.
- Supplier commitment: ChromaDex committed to purchase approximately $18.0 million of inventory from exclusive NR supplier W.R. Grace during 2023. The supply agreement was due to expire December 31, 2023, subject to renewal negotiations.
- Nestlé agreement: The amended five-year supply agreement provides for exclusive NHSc purchases of NRCL, tiered low-single-digit royalties on eligible product sales, and potential sales-based milestone payments. NHSc fulfilled an approximately $2.0 million initial purchase commitment in Q4 2022; $1.7 million was recorded under a bill-and-hold arrangement. No royalties or milestone payments were received in 2022.
- Funding and dilution: Two 2022 stock transactions generated approximately $7.7 million net proceeds, issuing shares to related-party investors and NHSc. The company reported approximately $47.8 million remaining under its ATM facility, but access depends on contractual conditions and market conditions. Additional financing may dilute shareholders.
- China venture: The venture’s planned commercialization depends on regulatory approvals, including China’s “Blue Hat” registration. Timing was uncertain at year-end 2022, and venture activity was not material in 2022.
- Litigation and contingencies: The Elysium disputes include multiple proceedings and appeals. A settlement was enforced in the Southern District of New York and that action was dismissed with prejudice, but appeals were pending at the filing date; a related California action was stayed pending a Federal Circuit appeal. In February 2023, the Federal Circuit affirmed invalidation of patents asserted in a separate Elysium patent case. The company stated it could not reasonably estimate possible loss for the SDNY matter and recorded no related loss accrual. Other disclosed matters include a licensor’s $1.6 million fee demand, which the company disputes, and prior FDA/FTC warning letters concerning COVID-19-related statements.
- Key operating risks: The company depends heavily on Tru Niagen, a limited number of suppliers (including Grace), major customers, consumer acceptance, marketing efficiency, regulatory compliance, and patent protection. A.S. Watson Group, a related party, represented 13.9% of 2022 sales and 36.6% of year-end receivables.
- Audited financial statements received an unqualified opinion from Marcum LLP. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to opine on internal-control effectiveness.
Important facts for investors to verify
- Confirm the issuer identity: this is ChromaDex Corporation (ticker CDXC), despite the request metadata naming Niagen Bioscience, Inc.
- Review cash burn, actual subsequent cash receipts, and financing needs against management’s 12-month liquidity expectation.
- Track fulfillment, pricing, and cash-conversion effects of the $18.0 million 2023 Grace inventory commitment and the supplier agreement’s renewal.
- Assess whether NHSc purchases, royalties, and milestone opportunities recur, and monitor the bill-and-hold revenue and deferred-revenue accounting.
- Follow the Elysium appeals and other legal matters for potential costs, damages, injunctions, or changes to recorded liabilities.
- Monitor gross-margin trends, customer concentration and receivable collections, China registration progress, and any further share issuance or dilution.